Furmonertinib Listed in Beijing Supplemental Medical Insurance Program

Beijing Puhui Jiankangbao, the only social security supplemental medical insurance product in Beijing directed by the Beijing Municipal Medical Insurance Bureau, is officially launched on July 26th. It includes in-patient and out-patient personal out-of-pocket expenses within the medical insurance catalog, in-patient personal out-of-pocket expenses outside the medical insurance catalog and 100 domestic and overseas expensive special medicines, covering 36 major diseases such as liver cancer, lung cancer, stomach cancer and leukemia.

Furmonertinib is successfully listed in the special medicines catalog, and Beijing Puhui Jiankangbao becomes the eighth local supplemental medical insurance to include Furmonertinib.

Domestic Special Medicines Category


Trade Name

Common Name








Lung Cancer

It is restricted to the treatment of adult patients of locally advanced or metastatic non-small cell lung cancer (NSCLC) who experience progression during or following prior therapy with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy with confirmed EGFR T790M positive mutations.

Unlike other cities’ insurance products, Beijing Puhui Jiankangbao expands the scope of special medicines to 100, covering 25 commonly-used domestic anti-cancer and local medicines and 75 special medicines available at the international medical institutions of Hainan Free Trade Port Boao Hope City. The deductible amount for healthy people is 20,000 YUAN and 60% reimbursement; and 40,000 YUAN and 30% respectively for those with specific anamnesis, with an annual coverage of 1 million YUAN (half for domestic special medicines and half for foreign ones).

Participants can purchase domestic special medicines at designated medical institutions, or through 19 designated pharmacies that provide direct payment and home delivery services.

Domestic Designated Pharmacies for 25 Domestic Special Medicines